GlassScriptPhysician profile
Megan M Johnson
NPI 1891090387
$6,156.53
in general payments reported to CMS, 2019-2025
23 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $1,958 · 2023: $3,006 · 2024: $441 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,321 · Food and Beverage: $1,708 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,321.10 |
| Food and Beverage | $1,708.34 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,757.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,529.28 | 2023 | Ultomiris |
| Abbott Laboratories | $1,463.89 | 2022-2025 | Cardiomems, Aveir, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.95 | 2023-2025 | Jardiance |
| Pfizer INC. | $140.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $131.14 | 2023-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $128.84 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $111.19 | 2021 | |
| Amgen INC. | $106.74 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $101.14 | 2021-2023 | |
| Novo Nordisk INC | $97.83 | 2024 | Wegovy, Ozempic |
| United Therapeutics Corporation | $91.65 | 2023 | Remodulin, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $69.70 | 2023-2025 | Verquvo |
| Janssen Biotech, INC. | $40.47 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $37.86 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.99 | 2023-2024 | Xarelto |
| Abiomed | $32.93 | 2025 | |
| Scpharmaceuticals INC. | $26.04 | 2025 | |
| Olympus America INC. | $17.06 | 2024 | Olympus |
| Daiichi Sankyo INC. | $16.16 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $16.00 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $13.39 | 2024 | Opsumit |
| Daxor Corporation | $10.91 | 2025 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.